Treatment for HIV Infections

Phase-Based Progress Estimates
Memorial University of Newfoundland, St. John's, Canada
HIV Infections+6 More
All Sexes
What conditions do you have?

Study Summary

Human Immunodeficiency Virus (HIV), hepatitis C (HCV), and syphilis are sexually transmitted and blood borne infections (STBBI) that affect millions of people worldwide and rates are rising in Canada. HCV and syphilis are curable, and HIV is treatable with virtually no risk of transmission to sexual partners when the infection is controlled, however, these outcomes require adequate testing. Unfortunately, an estimated 44% of Canadians living with HCV and 13% living with HIV are not diagnosed. These undiagnosed cases are the source of over half of new HIV infections. Furthermore, HIV-syphilis coinfection is common. Accessible testing forms a key pillar of an elimination strategy and acts as an access point for linking people to care. Community pharmacies are more accessible site for STBBI testing, compared to hospitals and doctors' offices. This is especially true for members of marginalized communities, some of whom are at higher risk of infection. The COVID-19 pandemic highlighted the need for low-barrier STBBI testing, as in-person healthcare services at doctors' offices and traditional screening clinics were scaled back. Pharmacies remained open throughout the pandemic. The APPROACH 2.0 study will assess the impact of a pharmacy-based testing program for HIV, hepatitis C, and syphilis in participating pharmacies in three Canadian provinces: Newfoundland & Labrador, Alberta, and Nova Scotia on finding new diagnoses and linkages with care. Participants will be offered point of care tests for HIV and/or HCV and/or a dry blood spot test which will test for HIV, HCV, and syphilis. These tests are easy to administer. Results from the point of care tests are available immediately during the pharmacy visit while participants will be contacted with dried blood spot test results when available (approximately 2 weeks). Participants with reactive tests are linked with confirmatory testing and care, and those with non-reactive results are offered preventative services including HIV PrEP (as indicated) and counselling. This study builds on a pilot study completed in 2017 (

Eligible Conditions

  • Syphilis Infection
  • HIV Infections
  • Hepatitis C Virus (HCV) Infection

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for HIV Infections

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Collected at the end of the study period (approximately one year)

Collected at the end of the study period (approximately one year)
Number and proportion of new HCV infections found through pharmacy testing in each province
Number and proportion of new HIV infections found through pharmacy testing in each province
Number and proportion of new syphilis infections found through pharmacy testing in each province

Trial Safety

Safety Progress

1 of 3

Other trials for HIV Infections

Trial Design

0 Treatment Group

1000 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: collected at the end of the study period (approximately one year)
Closest Location: Memorial University of Newfoundland · St. John's, Canada
2008First Recorded Clinical Trial
1 TrialsResearching HIV Infections
16 CompletedClinical Trials

Who is running the clinical trial?

Memorial University of NewfoundlandLead Sponsor
59 Previous Clinical Trials
1,763,184 Total Patients Enrolled
1 Trials studying HIV Infections
123 Patients Enrolled for HIV Infections

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.